Mikkel Bandak

Mikkel Bandak

Auto-generated profile, based on publicly available information

Mikkel Bandak

Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2016 in Andrology
Verified
Journal Article
Closed access
PDF file
MBM. Bandak
M. Bandak
NJNiels Jørgensen
Niels Jørgensen
AJA. Juul
A. Juul
IVI. R. Vogelius
I. R. Vogelius
JLJ. Lauritsen
J. Lauritsen
GDGedske Daugaard
Gedske Daugaard

1 January 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TWThomas Wagner
Thomas Wagner
BTBirgitte Grønkær Toft
Birgitte Grønkær Toft
JLJakob Lauritsen
Jakob Lauritsen
MBMikkel Bandak
Mikkel Bandak
ICIb Jarle Christensen
Ib Jarle Christensen
GDGedske Daugaard
Gedske Daugaard
PURPOSE: Approximately 20% of patients with clinical stage I seminoma relapse. Tumor size and rete testis invasion have been identified as risk factors for relapse. However, the level of evidence supporting the use of these risk factors in clinical decision making is low. Previous studies have been hampered by selection bias and variable pathology reporting that limit interpretation and generalization of results. We assessed prognostic factors for relapse in an unselected nationwide population-based setting with centralized pathology review. METHODS: Patients with clinical stage I seminoma diagnosed from January 2013 to December 2018 were identified in the prospective Danish Testicular Cancer database. By linkage to the Danish National Pathology Registry, histologic slides from the orchiectomy specimens were retrieved and reviewed blinded to the clinical outcome. Clinical data were obtained from medical records with follow-up until July 2022. The association between prespecified potential clinical and histopathologic prognostic factors and relapse was assessed by the use of Cox regression analysis. RESULTS: Of 924 patients included, 148 (16%) patients relapsed during a median follow-up of 6.3 years. Invasion of the testicular hilum (rete testis and hilar soft tissue), lymphovascular invasion, and elevated preorchiectomy levels of β-human chorionic gonadotropin and lactate dehydrogenase were independent predictors of relapse. The estimated 5-year risk of relapse ranged from 6% in patients with no risk factors to 62% in patients with all four risk factors with tumor extension into the hilar soft tissue of the testicular hilum. After internal model validation, the prognostic model had an overall concordance statistic of 0.70. CONCLUSION: The provided prognostic factors could replace current risk factors in guidelines and be used in future studies investigating risk-adapted follow-up and treatment strategies.

1 November 2011 in European Journal of Cancer
Verified
Journal Article
Closed access
MBMikkel Bandak
Mikkel Bandak
LALise Aksglaede
Lise Aksglaede
AJAnders Juul
Anders Juul
MRMikael Rørth
Mikael Rørth
GDGedske Daugaard
Gedske Daugaard

1 July 2018 in European Urology Focus
Verified
Journal Article
Closed access
MBMikkel Bandak
Mikkel Bandak
NJNiels Jørgensen
Niels Jørgensen
AJAnders Juul
Anders Juul
JLJakob Lauritsen
Jakob Lauritsen
MKMaria Gry Gundgaard Kier
Maria Gry Gundgaard Kier
GDGedske Daugaard
Gedske Daugaard

1 October 2018 in Journal of Urology
Verified
Journal Article
Open access
MBMikkel Bandak
Mikkel Bandak
JLJakob Lauritsen
Jakob Lauritsen
CJChristoffer Johansen
Christoffer Johansen
MKMichael Kreiberg
Michael Kreiberg
JSJulie Wang Skøtt
Julie Wang Skøtt
GDGedske Daugaard
Gedske Daugaard
Evidence on the long-term impact of testicular cancer treatment on sexual function is not clear. Our aim was to estimate the effect of testicular cancer treatment on the risk of sexual dysfunction in long-term survivors of testicular cancer. We performed a cross-sectional study of 2,260 long-term survivors of testicular cancer with a median followup of 17 years (IQR 12-24), including 1,098 who underwent orchiectomy alone (surveillance), 788 treated with bleomycin, etoposide and cisplatin alone or post-chemotherapy retroperitoneal surgery, 300 treated with abdominal radiotherapy and 74 who received more than 1 line of treatment. Sexual function was evaluated by the IIEF-15 (International Index of Erectile Function-15) questionnaire. Results were compared between treatment groups using logistic regression analysis with the results on each of the 5 IIEF-15 dimensions as the outcome and treatment as exposure using surveillance as the referent. The risk of erectile dysfunction was increased in all treatment groups compared to surveillance, including bleomycin, etoposide and cisplatin alone (OR 1.5, 95% CI 1.0-2.1, p <0.05), bleomycin, etoposide and cisplatin with post-chemotherapy surgery (OR 2.1, 95% CI 1.4-3.4, p <0.005), radiotherapy (OR 1.7, 95% CI 1.1-2.5, p <0.05) and more than 1 line of treatment (OR 3.2, 95% CI 1.6-6.3, p <0.005). Orgasmic dysfunction was associated with radiotherapy, bleomycin, etoposide and cisplatin with post-chemotherapy surgery and more than 1 line of treatment. Treatment with bleomycin, etoposide and cisplatin, radiotherapy and more than 1 treatment line increased the risk of erectile dysfunction in long-term survivors of testicular cancer compared to surveillance. Patients should be informed about this as part of the information on treatment related late effects.

1 February 2017 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MBMikkel Bandak
Mikkel Bandak
NJNiels Jørgensen
Niels Jørgensen
AJAnders Juul
Anders Juul
JLJakob Lauritsen
Jakob Lauritsen
MKMaria Gry Gundgaard Kier
Maria Gry Gundgaard Kier
GDGedske Daugaard
Gedske Daugaard